Loading market dashboard
Kane Biotech Inc.
KNE.VHealthcareTSXVCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Not for distribution to U. S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces that on May 28, 2026 it granted an aggregate of 9,750,000 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in accordance with the Company's third amended and restated stock option plan.
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") announces today its fourth quarter and full year 2025 financial results. Full Year 2025 Financial Highlights: Total revenue for the year ended December 31, 2025 was $427,869 compared to $2,080,879 for the year ended December 31, 2024.
